Display options
Cite
Solyanik O, Heimer M. Klinischer Stellenwert kontrastmittelfreier Kurzprotokolle in der Magnetresonanztomographie. [Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging]. Radiologe. 2021;61(9):810-817doi: 10.1007/s00117-021-00890-8.
Solyanik, O., & Heimer, M. (2021). Klinischer Stellenwert kontrastmittelfreier Kurzprotokolle in der Magnetresonanztomographie. [Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging]. Der Radiologe, 61(9), 810-817. https://doi.org/10.1007/s00117-021-00890-8
Solyanik, Olga, and Heimer, Maurice. "Klinischer Stellenwert kontrastmittelfreier Kurzprotokolle in der Magnetresonanztomographie." [Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging]. Der Radiologe vol. 61,9 (2021): 810-817. doi: https://doi.org/10.1007/s00117-021-00890-8
Solyanik O, Heimer M. Klinischer Stellenwert kontrastmittelfreier Kurzprotokolle in der Magnetresonanztomographie. [Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging]. Radiologe. 2021 Sep;61(9):810-817. doi: 10.1007/s00117-021-00890-8. Epub 2021 Jul 23. German. PMID: 34297140.
Copy Download .nbib Format: NLM
Share it on

Radiologe. 2021 Sep;61(9):810-817. doi: 10.1007/s00117-021-00890-8. Epub 2021 Jul 23.

[Clinical impact of abbreviated unenhanced prostate protocols in magnetic resonance imaging].

Der Radiologe

[Article in German]
Olga Solyanik, Maurice Heimer

Affiliations

  1. Klinik und Poliklinik für Radiologie, LMU-Klinikum, Marchioninistraße 15, 81377, München, Deutschland. [email protected].
  2. Klinik und Poliklinik für Radiologie, LMU-Klinikum, Marchioninistraße 15, 81377, München, Deutschland.

PMID: 34297140 DOI: 10.1007/s00117-021-00890-8

Abstract

BACKGROUND: According to the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 multiparametric magnetic resonance imaging (mpMRI) with gadolinium-(Gd)-based contrast agents is the diagnostic standard of care in the detection of prostate cancer (PCa). Recent data suggest equivalent performance of biparametric MRI (bpMRI) and mpMRI in defined indications.

OBJECTIVES: Evaluation of the current role of abbreviated or unenhanced protocols in MRI of the prostate in various clinical settings.

MATERIALS AND METHODS: Evaluation of clinical trials, guidelines and expert opinions.

RESULTS: The use of dynamic contrast-enhanced (DCE) MRI sequences is associated with contrast agent-associated risks and has significant impact on the imaging procedure and costs. Arguments for and against the use of contrast agent in prostate protocols as well as equivalence from bpMRI and mpMRI are discussed.

CONCLUSIONS: Currently, bpMRI can only be performed if very good image quality is available and in the hands of a radiologist with extensive experience in reading prostate MRI. There is a need for prospective studies to qualify bpMRI as the diagnostic method for the primary diagnosis of PCa.

© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Keywords: Biparametric magnetic resonance imaging; Gadolinium; Multiparametric magnetic resonance imaging; Prostate Imaging Reporting and Data System; Prostate cancer

References

  1. AWMF (2021) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021,AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ . Zugegriffen: 18. Mai 2021 - PubMed
  2. Turkbey B et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76(3):340–351 - PubMed
  3. Kamsut S, Reid K, Tan N (2020) Roundtable: arguments in support of using multi-parametric prostate MRI protocol. Abdom Radiol 45(12):3990–3996 - PubMed
  4. Bosaily AE et al (2020) Additional value of dynamic contrast-enhanced sequences in multiparametric prostate magnetic resonance imaging: data from the PROMIS study. Eur Urol 78(4):503–511 - PubMed
  5. Kang Z et al (2019) Abbreviated biparametric versus standard multiparametric MRI for diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 212(2):357–365 - PubMed
  6. Woo S et al (2018) Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 211(5):W226–W241 - PubMed
  7. Schoots IG et al (2015) Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68(3):438–450 - PubMed
  8. Franco FB, Fennessy FM (2020) Arguments against using an abbreviated or biparametric prostate MRI protocol. Abdom Radiol 45(12):3982–3989 - PubMed
  9. Ahmed HU et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389(10071):815–822 - PubMed
  10. Kasivisvanathan V et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777 - PubMed
  11. Kuhl CK et al (2017) Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285(2):493–505 - PubMed
  12. Di Campli E et al (2018) Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: comparison between readers with different experience. Eur J Radiol 101:17–23 - PubMed
  13. Scialpi M et al (2018) Abbreviated biparametric prostate MR imaging: is it really an alternative to multiparametric MR imaging? Radiology 286(1):360–361 - PubMed
  14. Christophe C et al (2020) Prostate cancer local staging using biparametric MRI: assessment and comparison with multiparametric MRI. Eur J Radiol 132:109350 - PubMed
  15. Ward R, Purysko AS (2020) Round table: arguments against using multiparametric prostate MRI protocols. Abdom Radiol 45(12):3997–4002 - PubMed
  16. Mason J et al (2018) Importance of dynamic contrast enhanced magnetic resonance imaging for targeting biopsy and salvage treatments after prostate cancer recurrence. J Contemp Brachytherapy 10(6):570–572 - PubMed
  17. van der Leest M et al (2019) High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naive men: the next step in magnetic resonance imaging accessibility. Eur Urol 76(5):574–581 - PubMed
  18. Scialpi M et al (2020) Round table: arguments in supporting abbreviated or biparametric MRI of the prostate protocol. Abdom Radiol 45(12):3974–3981 - PubMed
  19. Schoots IG et al (2021) PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. AJR Am J Roentgenol 216(1):3–19 - PubMed
  20. de Rooij M et al (2020) ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol 30(10):5404–5416 - PubMed
  21. Gatti M et al (2019) Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol 44(5):1883–1893 - PubMed
  22. Eldred-Evans D et al (2021) Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol 7(3):395–402 - PubMed
  23. Drost FH et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012663.pub2 - PubMed
  24. Kim CK et al (2008) MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am J Roentgenol 190(5):1180–1186 - PubMed
  25. Kitajima K et al (2015) Detection of local recurrence of prostate cancer after radical prostatectomy using endorectal coil MRI at 3 T: addition of DWI and dynamic contrast enhancement to T2-weighted MRI. AJR Am J Roentgenol 205(4):807–816 - PubMed
  26. Muller BG et al (2015) Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol 33(10):1503–1509 - PubMed
  27. Sun C et al (2021) T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol 31(1):325–332 - PubMed

MeSH terms

Publication Types